These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Understanding insulin: the old and new. Wilson HK; Field JB Adv Intern Med; 1984; 29():357-84. PubMed ID: 6369929 [No Abstract] [Full Text] [Related]
64. Resistance against subcutaneous insulin successfully managed with aprotinin. Müller WA; Taillens C; Léreret S; Berger M; Philippe J; Halban PA; Offord RE Lancet; 1980 Jun; 1(8180):1245-6. PubMed ID: 6155578 [No Abstract] [Full Text] [Related]
65. [Efficacy of aprotinin in insulin resistance caused by subcutaneous degradation of insulin]. Sudre Y; Marechaud R; Abadie JC; Rossi F; Gouet D Nouv Presse Med; 1982 Jan; 11(2):131-2. PubMed ID: 6173842 [No Abstract] [Full Text] [Related]
66. Insulin resistance: a common feature of diabetes mellitus. Kahn CR N Engl J Med; 1986 Jul; 315(4):252-4. PubMed ID: 3724817 [No Abstract] [Full Text] [Related]
67. Purified insulin preparations. Med Lett Drugs Ther; 1981 Jun; 23(12):53-4. PubMed ID: 7017365 [No Abstract] [Full Text] [Related]
70. [Unusual case of insulin resistance in a patient with a severe form of diabetes mellitus]. Pliats OM Probl Endokrinol (Mosk); 1983; 29(2):52-3. PubMed ID: 6344064 [No Abstract] [Full Text] [Related]
73. Control of diabetes with polyacrylamide implants containing insulin. Davis BK Experientia; 1972 Mar; 28(3):348. PubMed ID: 5026460 [No Abstract] [Full Text] [Related]
74. On the estimation of absorption of subcutaneous injected insulin from plasma concentrations using mathematical models. Cobelli C; Mari A; Duner E; Mollo F; Nosadini R Diabetologia; 1984 Apr; 26(4):314-6. PubMed ID: 6376240 [No Abstract] [Full Text] [Related]
77. The effects of diabetes and obesity on insulin degradation by human granulocytes [proceedings]. Dron DI; Brown PH; Thomas JH Biochem Soc Trans; 1980 Jun; 8(3):299. PubMed ID: 6995202 [No Abstract] [Full Text] [Related]
78. [WHAT IS THE MOST SUITABLE TIME TO ADMINISTER PROLONGED-ACTION INSULIN?]. MARIGO S Clin Ter; 1963 Sep; 26():548-56. PubMed ID: 14089596 [No Abstract] [Full Text] [Related]
79. [CLINICAL EVALUATIONS ON PRELIMINARY RESULTS WITH AN INSULIN WITH SEMIRETARDED ACTION]. MONTENERO P; COLLETTI A Clin Ter; 1965 Jun; 33():469-77. PubMed ID: 14341682 [No Abstract] [Full Text] [Related]
80. [Retard forms of insulin by matrix inclusion or complex formation]. Losse G; Müller F; Raddatz H; Naumann W; Kossowicz J Pharmazie; 1988 May; 43(5):355-7. PubMed ID: 3051057 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]